SG Americas Securities LLC grew its holdings in shares of AveXis, Inc. (NASDAQ:AVXS) by 41.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,224 shares of the company’s stock after buying an additional 2,113 shares during the quarter. SG Americas Securities LLC’s holdings in AveXis were worth $699,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Strs Ohio bought a new position in AveXis in the third quarter worth approximately $116,000. Botty Investors LLC bought a new position in AveXis in the second quarter worth approximately $123,000. Ameritas Investment Partners Inc. grew its stake in AveXis by 331.0% in the second quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock worth $174,000 after purchasing an additional 1,622 shares in the last quarter. Teacher Retirement System of Texas bought a new position in AveXis in the third quarter worth approximately $200,000. Finally, Deschutes Portfolio Strategy LLC bought a new position in AveXis in the third quarter worth approximately $203,000. 92.88% of the stock is currently owned by hedge funds and other institutional investors.
In other AveXis news, VP Andrew F. Knudten sold 2,000 shares of the stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $94.48, for a total transaction of $188,960.00. Following the sale, the vice president now directly owns 7,000 shares of the company’s stock, valued at approximately $661,360. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Brian K. Kaspar sold 15,000 shares of the stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $101.46, for a total value of $1,521,900.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 52,340 shares of company stock worth $5,172,298. 18.60% of the stock is owned by insiders.
AveXis (NASDAQ:AVXS) last released its earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.04). During the same quarter in the previous year, the business earned ($0.87) earnings per share. equities analysts forecast that AveXis, Inc. will post -6.23 EPS for the current fiscal year.
A number of research firms have weighed in on AVXS. Jefferies Group restated a “buy” rating and set a $108.00 target price (up previously from $92.00) on shares of AveXis in a report on Friday, August 11th. Chardan Capital restated a “buy” rating and set a $130.00 target price (up previously from $102.50) on shares of AveXis in a report on Friday, August 11th. BMO Capital Markets restated a “buy” rating and set a $123.00 target price on shares of AveXis in a report on Friday, August 11th. Citigroup upped their target price on AveXis from $100.00 to $116.00 and gave the stock a “buy” rating in a report on Monday, October 2nd. Finally, UBS restated a “buy” rating and set a $122.00 target price (up previously from $95.00) on shares of AveXis in a report on Tuesday, October 3rd. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and thirteen have issued a buy rating to the company’s stock. AveXis presently has a consensus rating of “Buy” and a consensus price target of $110.67.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Want to see what other hedge funds are holding AVXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AveXis, Inc. (NASDAQ:AVXS).
What are top analysts saying about AveXis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AveXis Inc. and related companies.